Köhler Hugo Fontan, Carvalho Genival Barbosa de, Kowalski Luiz Paulo
Department of Head and Neck Surgery and Otolaryngology, A C Camargo Cancer Center, São Paulo, SP, Brazil.
Department of Head and Neck Surgery, Universidade Estadual Paulista, São Paulo, SP, Brazil.
Int Arch Otorhinolaryngol. 2021 Nov 3;26(3):e370-e379. doi: 10.1055/s-0041-1726042. eCollection 2022 Jul.
Treatment of stage III laryngeal cancer suffered a major paradigm change with surgery being substituted by radiation therapy with chemotherapy. To evaluate the oncological outcome of different treatment modalities for stage III laryngeal cancer using a population database. A population database representing patients treated in the state of São Paulo, Brazil, was analyzed. Demographic, clinical and treatment variables were included, and the outcomes of interest were disease-specific and overall survival. Propensity score with nearest neighbor matching was used to compensate for imbalances in treatment groups. We retrieved data from 1,804 patients. In multivariate analysis, age, female gender, payment source, clinical N stage (cN) stages, and treatment modality were significant for disease-specific and overall survival. Patients submitted to surgery treatment had a significantly better disease-specific ( < 0.001) and overall survival ( < 0.001) compared with chemoradiation. Propensity score matching was based on cN stage, gender, age, topography, and payment modality, and allowed the pairing of 685 patients from each treatment modality. There was a significant difference in disease-specific survival favoring surgery-based treatment ( = 0.017). The treatment choice has a significant impact on survival in patients with stage III laryngeal cancer with surgery-based treatment being superior to chemoradiotherapy (CRT).
III期喉癌的治疗经历了重大的模式转变,手术被放化疗所取代。
使用人群数据库评估III期喉癌不同治疗方式的肿瘤学结局。
分析了代表巴西圣保罗州接受治疗患者的人群数据库。纳入了人口统计学、临床和治疗变量,感兴趣的结局是疾病特异性生存和总生存。采用倾向评分最近邻匹配来弥补治疗组之间的不均衡。
我们检索了1804例患者的数据。在多变量分析中,年龄、女性性别、支付来源、临床N分期(cN)以及治疗方式对疾病特异性生存和总生存有显著影响。与放化疗相比,接受手术治疗的患者疾病特异性生存(P<0.001)和总生存(P<0.001)显著更好。倾向评分匹配基于cN分期、性别、年龄、肿瘤部位和支付方式,使得每种治疗方式有685例患者配对。在疾病特异性生存方面,基于手术的治疗具有显著差异(P = 0.017)。
治疗选择对III期喉癌患者的生存有显著影响,基于手术的治疗优于放化疗(CRT)。